Multifocal cutaneous leishmaniasis in a patient treated with golimumab for psoriaticarthritis
Leishmaniasis is a zoonosis caused by protozoans transmitted by sandflies. Immu-nosuppression is a risk factor for developing leishmaniasis in patients treated with TNF inhibitors for autoimmune diseases. A 65-year-old man with a 14-year histo-ry of psoriatic arthritis in treatment with methotrexate, treated with golimumab during the last 2.5 years, presented ulcerations of the buttocks and upper back. Histopathological findings allowed us to yield the diagnosis of cutaneous leishman-iasis. Therapy was suspended and the patient underwent appropriate treatment. Five cases of leishmaniasis in patients treated with golimumab were reported in literature and ten cases were mentioned in retrospective reviews.
Authors
- Anna Silvia Biamonte
- Veronica Forte (ORCID: https://orcid.org/0009-0004-1128-6873)
- Massimo Menichini (ORCID: https://orcid.org/0009-0007-5996-9974)
- Luca Ventura
- Fabrizio Liberati
Institutions
- University of L'Aquila (IT)
- Ellis Hospital (US)
- San Salvatore Hospital (IT)
Publication Details
- Journal
- Polish Journal of Pathology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/pjp.2025.153977
- Citations
- 2
- Primary Topic
- Research on Leishmaniasis Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.76